Compare · REGN vs XBIT
REGN vs XBIT
Side-by-side comparison of Regeneron Pharmaceuticals Inc. (REGN) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both REGN and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- REGN is the larger of the two at $95.24B, about 1805.8x XBIT ($52.7M).
- REGN has been more active in the news (26 items in the past 4 weeks vs 7 for XBIT).
- REGN has more recent analyst coverage (25 ratings vs 0 for XBIT).
- Company
- Regeneron Pharmaceuticals Inc.
- XBiotech Inc.
- Price
- -
- -
- Market cap
- $95.24B
- $52.7M
- 1M return
- +12.42%
- -
- 1Y return
- +25.03%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2015
- News (4w)
- 26
- 7
- Recent ratings
- 25
- 0
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Latest REGN
- SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.
- FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS
- Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
- Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
- Director George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)
- EVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)
- Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)
- Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Latest XBIT
- Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.
- Director Simard John bought $143,409 worth of shares (70,000 units at $2.05), increasing direct ownership by 2% to 4,261,690 units (SEC Form 4)
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by XBiotech Inc.
- SEC Form 3 filed by XBiotech Inc.
- Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)
- SEC Form 8-K filed by XBiotech Inc.
- XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
- SEC Form DEF 14A filed by XBiotech Inc.